Cost-effectiveness of drug-eluting coronary stents in Quebec, Canada

International Journal of Technology Assessment in Health Care

Volumn 21, Issue 3, 2005, Pages 326-333

  Brophy, James M ^a,c   Erickson, Lonny J ^a,b,d  

^a MCGILL UNIVERSITY   (Canada)

^b Gouvernement du Quebec   (Canada)

^c ROYAL VICTORIA HOSPITAL   (Canada)

^d MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Cardiology; Coronary stents; Cost effectiveness

Indexed keywords

COST EFFECTIVENESS; COSTS; HEALTH RISKS; MATHEMATICAL MODELS; PATIENT MONITORING; PURCHASING; SENSITIVITY ANALYSIS;

BARE METAL CORONARY STENTS (BMS); COST-EFFECTIVENESS ANALYSIS; DRUG-ELUTING STENTS (DES); HIGH-RISK PATIENTS;

DRUG PRODUCTS;

ANGIOPLASTY; CANADA; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY STENT; COST EFFECTIVENESS ANALYSIS; DRUG ELUTING STENT; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH ECONOMICS; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HUMAN; MONTE CARLO METHOD; OUTCOMES RESEARCH; PERCUTANEOUS CORONARY INTERVENTION; REVIEW; TREATMENT OUTCOME;

EID: 23244439380     PISSN: 02664623     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0266462305050439     Document Type: Review

References (22)

1. Babapulle MN, Joseph L, Bélisle P, Brophy JM, Eisenberg MJ. A hierarchical Bayesian meta-analysis of randomized clinical trials of drug-related stents. Lancet. 2004;364:583-591.
2. Bolognese L. Le indicazioni all' uso degli stent a rilascio di farmaco. U.O. Malattie Cardiovascolari Osp. S. Donate Arezzo. Available at: http://www.regione.emilia-romagna.it/agenziasan/convegni/2004/2004_04.30_stent/ pomeriggio/Bolognese. pdf. Accessed October 7, 2004.
3. Brophy JM, Belisle P, Joseph L. Evidence for use of coronary stents. A hierarchical Bayesian meta-analysis. Ann Intern Med. 2003;138:777-786.
4. Bucher HC, Hengstler P, Schindler C, Guyatt GH. Percutaneous transluminal coronary angioplasty versus medical treatment for nonacute coronary heart disease: Meta analysis of randomised controlled trials . BMJ. 2000;321:73-77.
5. Cohen DJ, Bakhai A, Shi C, et al; on behalf of the SIRIUS Investigators. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: Results from the sirolimus-eluting balloon expandable stent in the treatment of patients with de novo native coronary artery lesions (SIRIUS) trial. Circulation. 2004;110:508-514.
6. Cohen EA, Young W, Slaughter PM, Oh P, Naylor CD. Trends in clinical and economic outcomes of coronary angioplasty from 1992 to 1995: A population-based analysis. Am Heart J. 1999;137:1012-1018.
7. Conseil d'évaluation des technologies de la santé. Revascularization techniques used in the treatment of stable angina pectoris. Quebec: Conseil d'évaluation des technologies de la santé; 1996.
8. Cutlip DE, Chhabra AG, Baim DS, et al. Beyond restenosis: Five-year clinical outcomes from second-generation coronary stent trials. Circulation. 2004;110:1226-1230.
9. Farb A, Sangiorgi G, Carter AJ, et al. Pathology of acute and chronic coronary stenting in humans. Circulation. 1999;99:44-52.
10. Greenberg D, Bakhai A, Cohen DJ . Do benefits of drug-eluting stents outweigh the costs? Am J Drug Delivery. 2003;1:255-266.
11. Hill R, Bagust A, Bakhai A, et al. Coronary artery stents: A rapid systematic review and economic evaluation. Health Technol Assess. Available at: http://www.nice.org.uk/pdf/Stents_Assessment_report.pdf. Accessed June 14 2004.
12. Hoffmann R, Mintz GS, Dussaillant GR, et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation. 1996;94:1247-1254.
13. Kaptchuk TJ. Effect of interpretive bias on research evidence. BMJ. 2003;326:1453-1455.
14. King SB. III. Restenosis: The mouse that roared. Circulation. 2003;108:248-249.
15. Komatsu R, Ueda M, Naruko T, Kojima A, Becker AE. Neointimal tissue response at sites of coronary stenting in humans: Macroscopic, histological, and immunohistochemical analyses. Circulation. 1998;98:224-233.
16. Lemos PA, Serruys PW, van Domburg RT, et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world." The rapamycin-eluting stent evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation. 2003;109:190-195.
17. Magaz S, Badia X, Annemans L, Lamotte M. Cost-effectiveness analysis of coronary revascularization techniques available for the treatment of ischemic heart disease. Value Health. 2003;6:668.
18. Mittmann N, Seung SJ, Brown A, Coyle D, Brophy JM, Cohen E. Economic evaluation of drug eluting stents. Canadian Cardiology Conference, Calgary Alberta, October 2004 (Abstract). Available at: http://www.pulsus.com/ccc2004/ abs/ a332.htm. Accessed 22 November 2004.
19. O'Brien BJ, Willan A, Blackhouse G, Goeree R, Cohen M, Goodman S. Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada? Am Heart J. 2000;139:423-429.
20. Rinfret S, Grines CL, Cosgrove RS, et al. Quality of life after balloon angioplasty or stenting for acute myocardial infarction. One-year results from the stent-PAMI trial. J Am Coll Cardiol. 2001;38:1614-1621.
21. Ruygrok PN, Melkert R, Morel MA, et al. Does angiography six months after coronary intervention influence management and outcome? Benestent II Investigators. J Am Coll Cardiol. 1999;34:1507-1511.
22. Wenk Lang A, Knight C. A cost-effectiveness analysis of TAXUS drug eluting stent in the UK. Value in Health. 2003; 6:661.